Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIN1 | Q13526 | 12/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.67 |
| ▸ | CASP1 | P29466 | 1/20 | 0.67 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.67 |
| ▸ | ERCC1 | P07992 | 2/20 | 0.61 |
| ▸ | FEN1 | P39748 | 2/20 | 0.61 |
| ▸ | ERCC4 | Q92889 | 2/20 | 0.61 |
| ▸ | RNASEH1 | O60930 | 1/20 | 0.61 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | PKM | P14618 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11564100 | 0.89 | PIN1 (0.81) | PIN1CYP1A2MAPK1CASP1CYP2C19 | |
| SCHEMBL5918226 | 0.88 | PIN1 (0.78) | PIN1CYP1A2MAPK1CASP1CYP2C19 | |
| SCHEMBL10650043 | 0.88 | PIN1 (0.78) | PIN1CYP1A2MAPK1CASP1CYP2C19 | |
| SCHEMBL30272215 | 0.85 | PIN1 (1.00) | PIN1CYP1A2MAPK1CASP1CYP2C19 | |
| SCHEMBL10649656 | 0.84 | PIN1 (0.72) | PIN1CYP1A2MAPK1CASP1CYP2C19 | |
| SCHEMBL8964151 | 0.83 | PIN1 (0.71) | PIN1CYP1A2MAPK1CASP1CYP2C19 | |
| SCHEMBL8963968 | 0.82 | PIN1 (0.69) | PIN1CYP1A2MAPK1CASP1CYP2C19 | |
| SCHEMBL28158003 | 0.81 | PIN1 (0.71) | PIN1CYP1A2MAPK1CASP1CYP2C19 | |
| SCHEMBL27475261 | 0.81 | PIN1 (0.68) | PIN1CYP1A2MAPK1CASP1CYP2C19 | |
| SCHEMBL29093221 | 0.80 | PIN1 (0.69) | PIN1CYP1A2MAPK1CASP1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8093400-B2 | Compounds useful in therapy | PFIZER INC. (US) | 2012-01-10 | — | — | US | disclosed |
| CN-1898244-B | Triazole derivatives as vasopressin antagonists | PFIZER | 2011-06-22 | — | — | CN | disclosed |
| US-20100317652-A1 | Compounds Useful In Therapy | PFIZER INC | 2010-12-16 | — | — | US | disclosed |
| US-7745630-B2 | Triazolyl piperidine arginine vasopressin receptor modulators | BRYANS JUSTIN STEPHEN | 2010-06-29 | — | — | US | disclosed |
| CN-1898244-A | Triazole derivatives as vasopressin antagonists | PFIZER (US) | 2007-01-17 | — | — | CN | disclosed |
| EP-1701959-A1 | TRIAZOLE DERIVATIVES AS VASOPRESSIN ANTAGONISTS | Pfizer Limited (GB) | 2006-09-20 | — | — | EP | disclosed |
| WO-2005063754-A1 | TRIAZOLE DERIVATIVES AS VASOPRESSIN ANTAGONISTS | PFIZER LIMITED (GB) | 2005-07-14 | — | — | WO | disclosed |
| US-20050154024-A1 | Compounds useful in therapy | PFIZER INC | 2005-07-14 | — | — | US | disclosed |
| EP-1093367-A4 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2003-03-05 | — | — | EP | disclosed |
| EP-1093367-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-04-25 | — | — | EP | disclosed |
| WO-1999066925-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050154024-A1 | Compounds useful in therapy | PTGER4, PTGER3, ALOX5 | PIN1 3349/4885CYP1A2 285/4885MAPK1 3698/4885 |
| US-20100317652-A1 | Compounds Useful In Therapy | AVPR1A, AVPR1B, AVPR2 | PIN1 1691/4885CYP1A2 507/4885MAPK1 3198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.